420 related articles for article (PubMed ID: 28497201)
1. Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells.
Wiatr K; Szlachcic WJ; Trzeciak M; Figlerowicz M; Figiel M
Mol Neurobiol; 2018 Apr; 55(4):3351-3371. PubMed ID: 28497201
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal instability during neurogenesis in Huntington's disease.
Ruzo A; Croft GF; Metzger JJ; Galgoczi S; Gerber LJ; Pellegrini C; Wang H; Fenner M; Tse S; Marks A; Nchako C; Brivanlou AH
Development; 2018 Jan; 145(2):. PubMed ID: 29378824
[TBL] [Abstract][Full Text] [Related]
4. Cellular Models: HD Patient-Derived Pluripotent Stem Cells.
Geater C; Hernandez S; Thompson L; Mattis VB
Methods Mol Biol; 2018; 1780():41-73. PubMed ID: 29856014
[TBL] [Abstract][Full Text] [Related]
5. The Generation of Mouse and Human Huntington Disease iPS Cells Suitable for
Szlachcic WJ; Wiatr K; Trzeciak M; Figlerowicz M; Figiel M
Front Mol Neurosci; 2017; 10():253. PubMed ID: 28848389
[TBL] [Abstract][Full Text] [Related]
6. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
7. RNA toxicity induced by expanded CAG repeats in Huntington's disease.
Martí E
Brain Pathol; 2016 Nov; 26(6):779-786. PubMed ID: 27529325
[TBL] [Abstract][Full Text] [Related]
8. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
[TBL] [Abstract][Full Text] [Related]
9. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.
HD iPSC Consortium
Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968
[TBL] [Abstract][Full Text] [Related]
10. Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.
Wright GEB; Collins JA; Kay C; McDonald C; Dolzhenko E; Xia Q; Bečanović K; Drögemöller BI; Semaka A; Nguyen CM; Trost B; Richards F; Bijlsma EK; Squitieri F; Ross CJD; Scherer SW; Eberle MA; Yuen RKC; Hayden MR
Am J Hum Genet; 2019 Jun; 104(6):1116-1126. PubMed ID: 31104771
[TBL] [Abstract][Full Text] [Related]
11. Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach.
Mariani LL; Tesson C; Charles P; Cazeneuve C; Hahn V; Youssov K; Freeman L; Grabli D; Roze E; Noël S; Peuvion JN; Bachoud-Levi AC; Brice A; Stevanin G; Durr A
JAMA Neurol; 2016 Sep; 73(9):1105-14. PubMed ID: 27400454
[TBL] [Abstract][Full Text] [Related]
12. Three Huntington's Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes.
Jacquet L; Neueder A; Földes G; Karagiannis P; Hobbs C; Jolinon N; Mioulane M; Sakai T; Harding SE; Ilic D
PLoS One; 2015; 10(5):e0126860. PubMed ID: 25993131
[TBL] [Abstract][Full Text] [Related]
13. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
[TBL] [Abstract][Full Text] [Related]
14. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
Conforti P; Camnasio S; Mutti C; Valenza M; Thompson M; Fossale E; Zeitlin S; MacDonald ME; Zuccato C; Cattaneo E
Neurobiol Dis; 2013 Feb; 50():160-70. PubMed ID: 23089356
[TBL] [Abstract][Full Text] [Related]
15. Huntington's Disease: Relationship Between Phenotype and Genotype.
Sun YM; Zhang YB; Wu ZY
Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
[TBL] [Abstract][Full Text] [Related]
16. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons.
Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E
Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602
[TBL] [Abstract][Full Text] [Related]
17. Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.
Bard J; Wall MD; Lazari O; Arjomand J; Munoz-Sanjuan I
J Biomol Screen; 2014 Feb; 19(2):191-204. PubMed ID: 24196395
[TBL] [Abstract][Full Text] [Related]
18. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
20. Use of human stem cells in Huntington disease modeling and translational research.
Golas MM; Sander B
Exp Neurol; 2016 Apr; 278():76-90. PubMed ID: 26826449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
